Wall Street analysts think Facebook's cryptocurrency payments project will give the company a big boost.Marketsread more
Facebook's reported move into cryptocurrency could amount to the biggest catalyst for digital assets in their decade-long history, some crypto investors say.Bitcoinread more
In a 7-2 ruling, over dissents from Justices Ruth Bader Ginsburg and Neil Gorsuch, the justices affirmed the so-called "dual sovereignty" exception to the Constitution's...Politicsread more
A recent Fed survey showed that workers' confidence for finding a new job after losing their current position was at 61.5% in May.Economyread more
The Fed is expected to cut rates multiple times, but the reason behind those cuts could have vastly different implications for the market.Marketsread more
The "captive carry flight test" evaluates the mock weapon during flight and is the Air Force's latest step amid the budding hypersonic arms race between China and Russia.Politicsread more
"This is going to be the biggest thing that's happened to Facebook in years," says CNBC's Jim Cramer. "It will be vital."Investingread more
Airbus recorded orders and options for 123 planes, according to the aviation consulting firm IBA.iQ.Airlinesread more
European aircraft manufacturer Airbus is betting travelers will want to fly long distances on smaller jets with the launch of its Airbus A321 XLR.Airlinesread more
The action reflects the evolving dynamic for U.S. companies that have done business with Huawei, which has been caught in the middle of growing U.S.-China trade tension.Technologyread more
The announcement comes after Trump blasted three countries because thousands of their citizens had sought asylum at the U.S. border with Mexico.Politicsread more
Lundbeck, which funds research and development for drugs that combat depression, schizophrenia and other mental illnesses, strikes a balance between high-value products and generic alternatives that shields the company from such criticisms, Schultz said Monday on CNBC's "Closing Bell. "
"It does cost billions of dollars to make a new drug, but of course there's also patent expiry and then drugs become very cheap," Schultz said. "And that's the case with, for instance, antidepressants, where the generics are more than 90 percent of the market."
"So we have very cheap therapies, but also new innovative therapies, which will be higher value but also higher cost per patient," he said.
Lundbeck stock fell 1.05 percent on Monday. Sixty-one percent of Lundbeck's sales came from North America in the first half of 2017.
Earlier Monday, Trump lashed out at Merck CEO Kenneth Frazier for stepping down from the American Manufacturing Council over the president's equivocal response to a white nationalist protest that turned deadly in Charlottesville, Virginia, on Saturday.
"Now that Ken Frazier of Merck Pharma has resigned from President's Manufacturing Council," the president tweeted, "he will have more time to LOWER RIPOFF DRUG PRICES!"
"As CEO of Merck and as a matter of personal conscience, I feel a responsibility to take a stand against intolerance and extremism," Frazier, who is African-American, said in a statement tweeted Monday morning.
Asked if he was concerned about the president's willingness to take aim at pharmaceutical companies, Schultz said Lundbeck has nothing to worry about.
"We always feel we provide value in all the products we've been bringing to the market, so we don't think we have ever seen, from our company, ripoff prices," Schultz said.
"I know there have been episodes with other, smaller companies in the United States, which is very regrettable," he said. "But in our case, we believe we bring true value to the patients."